Active Agent-Eluting Gelatin Hemostatic Matrix for SSI Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing surgical site infections (SSIs) are inadequate, particularly in orthopedic surgeries, as they often lead to increased medical costs, prolonged hospital stays, and antibiotic resistance, despite the use of antimicrobial prophylaxis and hemostatic agents.
Innovation Solution
A biodegradable hemostatic agent is developed by conjugating antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs) to gelatin through peptide bond formation, allowing for both immediate and sustained release of active agents to prevent infections and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antimicrobial prophylaxis and hemostatic agents are used separately, then infection prevention and hemostasis are achieved, but medical costs increase and hospital stays are prolonged
Solution Approach 1:
The patent combines hemostatic agents and antimicrobial drugs into a single integrated composition. The hemostatic agent matrix incorporates antimicrobial compounds that are released at the surgical site, providing both hemostasis and infection prevention simultaneously. This eliminates the need for separate applications of hemostatic agents and antimicrobial prophylaxis, thereby reducing medical costs and hospital stay duration while maintaining reliable infection prevention efficacy.
2Reliability
If conventional antimicrobial prophylaxis is used, then infection prevention is achieved, but antibiotic resistance increases
Solution Approach 1:
The patent delivers antimicrobial agents locally at the surgical site through the hemostatic agent matrix, rather than systemic administration. This localized delivery ensures high concentrations of antimicrobial compounds are present where needed to prevent infection, while minimizing systemic exposure that could contribute to antibiotic resistance. The hemostatic agent serves as a localized reservoir that releases antimicrobials directly at the wound bed.
3Reliability
If systemic antibiotic administration is used, then infection prevention is achieved, but unnecessary systemic exposure occurs
Solution Approach 1:
The patent extracts the antimicrobial function from systemic administration and delivers it locally through the hemostatic agent at the surgical site. The antimicrobial compounds are incorporated into the hemostatic matrix and released locally, eliminating the need for systemic antibiotic administration. This provides effective infection prevention while avoiding unnecessary systemic exposure and its associated side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The agent provides controlled release of antibiotics and NSAIDs, reducing the risk of SSIs and antibiotic resistance, while minimizing systemic antibiotic administration and promoting wound healing.
Implementation Method 1
conjugating antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs) to gelatin through peptide bond formation
Implementation Method 2
The highly hydrophilic nature of gelatin allows for drug absorption in the form of a hydrogel and controlled drug release through a degradation or diffusion-controlled mechanism
Data Source
AI summary
A novel active agent-eluting hemostatic agent and methods of use and manufacture thereof are presented. A polymer, such as gelatin, is used as the base for a hemostatic agent. The gelatin is crosslinked with a chemical crosslinker, such as a carbodiimide, in the presence of an active agent. The active agent may be an anesthetic or antimicrobial, such as an antibiotic. The novel process allows for the active agent to be both covalently bound to the gelatin as well as be trapped within cages in the gelatin that are formed from the crosslinking. This dual measure allows for controlled and sustained release of the active agent from the hemostatic agent to reduce surgical site infections.